Array Biopharma Inc
ARRY
ARRY was delisted on the 29th of July, 2019.
235 hedge funds and large institutions have $3.22B invested in Array Biopharma Inc in 2018 Q1 according to their latest regulatory filings, with 66 funds opening new positions, 83 increasing their positions, 62 reducing their positions, and 20 closing their positions.
230% more first-time investments, than exits
New positions opened: 66 | Existing positions closed: 20
46% more call options, than puts
Call options by funds: $27.3M | Put options by funds: $18.7M
34% more repeat investments, than reductions
Existing positions increased: 83 | Existing positions reduced: 62
26% more capital invested
Capital invested by funds: $2.56B → $3.22B (+$660M)
23% more funds holding
Funds holding: 191 → 235 (+44)
0% more funds holding in top 10
Funds holding in top 10: 7 → 7 (0)
Top Buyers
Top Sellers
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$84.3M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
-$58M |
| 3 |
ACA
Avoro Capital Advisors
New York
|
-$56.8M |
| 4 |
O
OrbiMed
New York
|
-$43.6M |
| 5 |
Morgan Stanley
New York
|
-$33.7M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AIS
251
AlphaOne Investment Services
West Chester,
Pennsylvania
| – | -$33K | -2,570 | Closed |
|
|
TWA
252
TCI Wealth Advisors
Tucson,
Arizona
| – | -$5K | -400 | Closed |
|
253
Envestnet Asset Management
Chicago,
Illinois
| – | -$3K | -269 | Closed |
|
|
DCM
254
Delpha Capital Management
New York
| – | -$1K | -75 | Closed |
|
|
ML
255
McAdam LLC
Philadelphia,
Pennsylvania
| – | +$400 | +25 | New |
|
ARRY Hedge Fund Activity: Q1 2018 in Review
235 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Array Biopharma Inc (ARRY) for Q1 2018, worth a combined $3.22B — up 26% from $2.56B a quarter earlier.
Buyers outnumbered sellers: 66 funds opened new ARRY positions and 20 closed out — a net gain of 46 holders — while 83 added to existing stakes and 62 trimmed.
The largest buyer was Farallon Capital Management, opening a new position worth an estimated $49.6M. The largest seller was Point72 Asset Management, cutting an estimated $84.3M.
- 235 institutional investors held Array Biopharma Inc (ARRY) as of Q1 2018, up from 191 in Q4 2017.
- Funds reported $3.22B of Array Biopharma Inc stock for Q1 2018, up 26% quarter-over-quarter.
- 66 funds opened new Array Biopharma Inc positions in Q1 2018 and 20 closed out, a net change of +46 holders.
- The largest Array Biopharma Inc buyer in Q1 2018 was Farallon Capital Management, an estimated $49.6M added.
- The largest Array Biopharma Inc seller in Q1 2018 was Point72 Asset Management, an estimated $84.3M sold.
Based on aggregated 13F filings for Q1 2018.